Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours

por De Giorgi, U, Rosti, G, Slavin, S, Yaniv, I, Harousseau, J L, Ladenstein, R, Demirer, T, Dini, G
Publicado 2005

Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients

por Mego, M, De Giorgi, U, Broglio, K, Dawood, S, Valero, V, Andreopoulou, E, Handy, B, Reuben, J M, Cristofanilli, M
Publicado 2009

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis

por Maiorano, B.A., De Giorgi, U., Roviello, G., Messina, C., Altavilla, A., Cattrini, C., Mennitto, A., Maiello, E., Di Maio, M.
Publicado 2022

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide

por Del Re, M., Conteduca, V., Crucitta, S., Gurioli, G., Casadei, C., Restante, G., Schepisi, G., Lolli, C., Cucchiara, F., Danesi, R., De Giorgi, U.
Publicado 2021

Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

por Santoni, M, De Giorgi, U, Iacovelli, R, Conti, A, Burattini, L, Rossi, L, Luca Burgio, S, Berardi, R, Muzzonigro, G, Cortesi, E, Amadori, D, Cascinu, S
Publicado 2013

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer

por Cursano, M. C., Conteduca, V., Scarpi, E., Gurioli, G., Casadei, C., Gargiulo, S., Altavilla, A., Lolli, C., Vincenzi, B., Tonini, G., Santini, D., De Giorgi, U.
Publicado 2022

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone

por Salvi, S, Casadio, V, Conteduca, V, Burgio, S L, Menna, C, Bianchi, E, Rossi, L, Carretta, E, Masini, C, Amadori, D, Calistri, D, Attard, G, De Giorgi, U
Publicado 2015

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prost...

por Conteduca, V., Scarpi, E., Caroli, P., Salvi, S., Lolli, C., Burgio, S. L., Menna, C., Schepisi, G., Testoni, S., Gurioli, G., Paganelli, G., Casadio, V., Matteucci, F., De Giorgi, U.
Publicado 2017

A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)

por Cortesi, L., Venturelli, M., Cortesi, G., Caggia, F., Toss, A., Barbieri, E., De Giorgi, U., Guarneri, V., Musolino, A., De Matteis, E., Zambelli, A., Bisagni, G., Dominici, M.
Publicado 2023

COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic...

por Silvestris, N., Di Maio, M., Russo, A., Chiari, R., De Giorgi, U., Del Mastro, L., Giuffrida, D., La Verde, N., Perrone, F., Tucci, M., Beretta, G.D., Cinieri, S.
Publicado 2021

Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients

por Del Re, M., Omarini, C., Diodati, L., Palleschi, M., Meattini, I., Crucitta, S., Lorenzini, G., Isca, C., Fontana, A., Livi, L., Piacentini, F., Fogli, S., De Giorgi, U., Danesi, R.
Publicado 2021

Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients

por Del Re, M., Omarini, C., Diodati, L., Palleschi, M., Meattini, I., Crucitta, S., Lorenzini, G., Isca, C., Fontana, A., Livi, L., Piacentini, F., Fogli, S., De Giorgi, U., Danesi, R.
Publicado 2022

Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer

por Mego, M, Gao, H, Cohen, EN, Anfossi, S, Giordano, A, Sanda, T, Fouad, TM, De Giorgi, U, Giuliano, M, Woodward, WA, Alvarez, RH, Valero, V, Ueno, NT, Hortobagyi, GN, Cristofanilli, M, Reuben, JM
Publicado 2016

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

por Russo, A., Incorvaia, L., Capoluongo, E., Tagliaferri, P., Gori, S., Cortesi, L., Genuardi, M., Turchetti, D., De Giorgi, U., Di Maio, M., Barberis, M., Dessena, M., Del Re, M., Lapini, A., Luchini, C., Jereczek-Fossa, B.A., Sapino, A., Cinieri, S.
Publicado 2022

LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhib...

por Bersanelli, M., Giannarelli, D., Verzoni, E., Buti, S., De Giorgi, U., Clemente, A., Filetti, M., Di Napoli, M., Calvetti, L., Ermacora, P., Catino, A.M., Guaitoli, G., Bonomo, P., Mazzoni, F., Veccia, A., Grosso, F., Maruzzo, M., Rossi, E., Grossi, F., Procopio, G.
Publicado 2020

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

por Fornarini, G., Rebuzzi, S.E., Banna, G.L., Calabrò, F., Scandurra, G., De Giorgi, U., Masini, C., Baldessari, C., Naglieri, E., Caserta, C., Manacorda, S., Maruzzo, M., Milella, M., Buttigliero, C., Tambaro, R., Ermacora, P., Morelli, F., Nolè, F., Astolfi, C., Sternberg, C.N.
Publicado 2021

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-cont...

por Ledermann, J.A., Zurawski, B., Raspagliesi, F., De Giorgi, U., Arranz Arija, J., Romeo Marin, M., Lisyanskaya, A., Póka, R.L., Markowska, J., Cebotaru, C., Casado Herraez, A., Colombo, N., Kutarska, E., Hall, M., Jacobs, A., Ahrens-Fath, I., Baumeister, H., Zurlo, A., Sehouli, J.
Publicado 2021

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

por Rebuzzi, S.E., Signori, A., Buti, S., Banna, G.L., Murianni, V., Damassi, A., Maruzzo, M., Giannarelli, D., Tortora, G., Galli, L., Rizzo, M., De Giorgi, U., Antonuzzo, L., Bracarda, S., Cartenì, G., Atzori, F., Tamberi, S., Procopio, G., Fratino, L., Lo Re, G., Santoni, M., Baldessari, C., Astone, A., Calabrò, F., Brunelli, M., Porta, C., Rescigno, P., Basso, U., Fornarini, G.
Publicado 2022

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative b...

por Conteduca, V., Wetterskog, D., Sharabiani, M. T. A., Grande, E., Fernandez-Perez, M. P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vazquez-Estevez, S., González del Alba, A., Mellado, B., Fernandez-Calvo, O., Méndez-Vidal, M. J., Climent, M. A., Duran, I., Gallardo, E., Rodriguez, A., Santander, C., Sáez, M. I., Puente, J., Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., De Giorgi, U., Gonzalez-Billalabeitia, E., Attard, G.
Publicado 2017

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/...

por Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D’Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., Poveda, A.
Publicado 2023